Sorafenib therapy for advanced hepatocellular carcinoma with Vp3 or 4 portal vein tumor thrombosis

Teiji Kuzuya, Kaoru Tsuchiya, Keisuke Tanaka, Yuichiro Suzuki, Takahide Hoshioka, Shinji Tamaki, Tomoji Kato, Yutaka Yasui, Takahiro Hosokawa, Ken Ueda, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Masayuki Kurosaki, Yasuhiro Asahina, Namiki Izumi

研究成果: Article査読

抄録

We investigated efficacy of sorafenib therapy for advanced hepatocellular carcinoma (HCC) with Vp3/4 portal vein tumor thrombosis. According to modified RECIST, the therapeutic responses in Vp0/2 group (n=30) were 8 PR, 14 SD and 8 PD cases, and while those in Vp3/4 group (n=11) were 5 PR, 2 SD and 4 PD cases. The response rates and cumulative progression rates were not significantly different between two groups. The cumulative survival rates in Vp3/4 group were significantly lower than those in Vp0/2 group. The deteriorations of Child-Pugh scores in Vp3/4 group were significantly higher than those in Vp0/2 group. The possibility of the deterioration of liver function should be kept in mind during sorafenib therapy for advanced HCC with Vp3/4.

本文言語English
ページ(範囲)325-326
ページ数2
ジャーナルActa Hepatologica Japonica
52
5
DOI
出版ステータスPublished - 2011
外部発表はい

All Science Journal Classification (ASJC) codes

  • Hepatology

フィンガープリント 「Sorafenib therapy for advanced hepatocellular carcinoma with Vp3 or 4 portal vein tumor thrombosis」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル